Logo image of BBNX

BETA BIONICS INC (BBNX) Stock Fundamental Analysis

NASDAQ:BBNX - Nasdaq - US08659B1026 - Common Stock - Currency: USD

16.42  +0.02 (+0.12%)

After market: 16.3 -0.12 (-0.73%)

Fundamental Rating

3

BBNX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. While BBNX has a great health rating, there are worries on its profitability. While showing a medium growth rate, BBNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BBNX had negative earnings in the past year.
In the past year BBNX has reported a negative cash flow from operations.
BBNX Yearly Net Income VS EBIT VS OCF VS FCFBBNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -36.59%, BBNX is not doing good in the industry: 60.96% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -72.04%, BBNX is in line with its industry, outperforming 41.71% of the companies in the same industry.
Industry RankSector Rank
ROA -36.59%
ROE -72.04%
ROIC N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBNX Yearly ROA, ROE, ROICBBNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

Looking at the Gross Margin, with a value of 55.11%, BBNX is in line with its industry, outperforming 50.80% of the companies in the same industry.
BBNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBNX Yearly Profit, Operating, Gross MarginsBBNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

BBNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BBNX remains at a similar level compared to 1 year ago.
BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBNX Yearly Shares OutstandingBBNX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
BBNX Yearly Total Debt VS Total AssetsBBNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M

2.2 Solvency

BBNX has an Altman-Z score of 3.37. This indicates that BBNX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BBNX (3.37) is better than 70.59% of its industry peers.
There is no outstanding debt for BBNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.37
ROIC/WACCN/A
WACC8.87%
BBNX Yearly LT Debt VS Equity VS FCFBBNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

BBNX has a Current Ratio of 6.29. This indicates that BBNX is financially healthy and has no problem in meeting its short term obligations.
BBNX has a Current ratio of 6.29. This is amongst the best in the industry. BBNX outperforms 82.89% of its industry peers.
BBNX has a Quick Ratio of 5.66. This indicates that BBNX is financially healthy and has no problem in meeting its short term obligations.
BBNX has a better Quick ratio (5.66) than 84.49% of its industry peers.
Industry RankSector Rank
Current Ratio 6.29
Quick Ratio 5.66
BBNX Yearly Current Assets VS Current LiabilitesBBNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for BBNX have decreased strongly by -24.17% in the last year.
The Revenue has grown by 442.93% in the past year. This is a very strong growth!
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.93%
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.79%

3.2 Future

The Earnings Per Share is expected to grow by 2.72% on average over the next years.
BBNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.70% yearly.
EPS Next Y-4.72%
EPS Next 2Y2.41%
EPS Next 3Y2.72%
EPS Next 5YN/A
Revenue Next Year30.6%
Revenue Next 2Y33.94%
Revenue Next 3Y34.7%
Revenue Next 5YN/A

3.3 Evolution

BBNX Yearly Revenue VS EstimatesBBNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 50M 100M 150M
BBNX Yearly EPS VS EstimatesBBNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BBNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BBNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBNX Price Earnings VS Forward Price EarningsBBNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBNX Per share dataBBNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.41%
EPS Next 3Y2.72%

More info and screens

0

5. Dividend

5.1 Amount

BBNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BETA BIONICS INC

NASDAQ:BBNX (8/4/2025, 8:00:01 PM)

After market: 16.3 -0.12 (-0.73%)

16.42

+0.02 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)N/A N/A
Inst Owners93.3%
Inst Owner Change0.08%
Ins Owners6.51%
Ins Owner Change7.43%
Market Cap713.78M
Analysts84
Price Target24.03 (46.35%)
Short Float %12.53%
Short Ratio9.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.6%
EPS NY rev (3m)-18.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.56%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)2.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.96
P/FCF N/A
P/OCF N/A
P/B 9.39
P/tB 9.39
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS1.5
BVpS1.75
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.59%
ROE -72.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.11%
FCFM N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 148.71%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.29
Quick Ratio 5.66
Altman-Z 3.37
F-Score5
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)68.31%
Cap/Depr(5y)N/A
Cap/Sales(3y)146.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.93%
EPS Next Y-4.72%
EPS Next 2Y2.41%
EPS Next 3Y2.72%
EPS Next 5YN/A
Revenue 1Y (TTM)442.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.79%
Revenue Next Year30.6%
Revenue Next 2Y33.94%
Revenue Next 3Y34.7%
Revenue Next 5YN/A
EBIT growth 1Y-26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.99%
EBIT Next 3Y-18.61%
EBIT Next 5YN/A
FCF growth 1Y-57.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.78%
OCF growth 3YN/A
OCF growth 5YN/A